List view / Grid view
18 March 2014 | By Lundbeck
Denmark is the first country in Europe where Abilify Maintena® is fully reimbursed and accessible to people diagnosed with schizophrenia...
23 December 2013 | By Lundbeck
New research reveals that genetic variations that increase the risk of developing schizophrenia have a direct and harmful effect on the brain, impairing the intellectual and cognitive function of people with these variations...
In this Process Analytical Technology (PAT) In-Depth Focus: Presenting a rational approach to QbD-based pharmaceutical development: A roller compaction case study, PAT for pharmaceutical spray drying, PAT Roundtable, Show Preview: IFPAC® 2014...
3 December 2013 | By Lundbeck
Jacob Tolstrup, Lundbeck's Vice President for Business Development, will now also be in charge of the company's HR department. The Vice President for HR, Teddy Hebo Larsen, has resigned at his own request...
14 October 2013 | By H. Lundbeck A/S
The Michael J. Fox Foundation has donated 5.5 million kroner to two Danish research projects in Parkinson's disease...
21 September 2013 | By
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation for the maintenance treatment of schizophrenia in adult patients stabilised…
20 June 2013 | By H. Lundbeck A/S
Lundbeck's initiative could lead to a reduction of around 50-55 positions in Europe...
22 April 2013 | By H. Lundbeck A/S
Lundbeck launches Selincro®...
8 April 2013 | By H. Lundbeck A/S
New data on Selincro from three phase III studies that show a significant reduction in alcohol consumption in alcohol dependent patients with high risk drinking level...
20 March 2013 | By H. Lundbeck A/S
Results add to evidence for Azilect as an effective and well-tolerated treatment option at different stages of the progression of PD...
14 January 2013 | By H. Lundbeck A/S
Lundbeck took first place in a global survey, in which 600 patient groups around the world evaluated the ability of 29 pharmaceutical companies to meet patient expectations...
11 January 2013 | By H. Lundbeck A/S
The move strengthens the company's capacity to bring drugs to market effectively...
28 August 2012 | By H. Lundbeck A/S
Lundbeck announced that Health Canada has approved Treanda® following the success of the brand in both Europe and the US...
22 August 2012 | By H. Lundbeck A/S
Lundbeck has appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president...
8 August 2012 | By H. Lundbeck A/S
H. Lundbeck A/S reports first half revenue of DKK 6,829 million...
